MDT — Medtronic plc.
Is MDT overbought or oversold? Here is the current MarketMoodz read.
Medtronic plc. (MDT) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $102.88. The rating moved from Overbought to Neutral on November 12, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$102.88
- Last changeMoved from Overbought to Neutral on November 12, 2026
- SectorHealthcare
- IndustryMedical Devices
AI analysis
Medtronic is a cash-generative, diversified medical-device leader with durable revenue streams from implants, disposables and services. The company benefits from secular tailwinds—aging demographics and expanded device indications—plus the financial flexibility to invest in R&D and make strategic acquisitions. Near-term stability is supported by an installed base and replacement cycles, and sector flows into large-cap healthcare provide defensive support. Key challenges include regulatory/product-safety exposure, reimbursement/pricing pressure, elective-procedure sensitivity, and competitive dynamics. Overall upside catalysts include stronger procedure volumes, successful commercialization of new devices and margin improvement from operational initiatives.
Key factors
- Large, diversified medical-devices portfolio with recurring revenue from implants, disposables and service contracts
- Strong free cash flow and healthy balance sheet that support R&D, tuck-in M&A and share repurchases
- Defensive demand characteristics versus broader cyclicals; flows into large-cap healthcare in risk-off/risk-on rotations
- Favorable secular drivers: aging population, chronic disease management, and expanding indications for device therapies
- Operational cadence: steady earnings visibility from installed base and replacement cycles, limiting near-term volatility
- Opportunities for margin expansion via cost efficiencies and higher-margin specialty products and services
Risks
- Regulatory and product-safety risks including recalls or post-market actions that can hit revenue and reputation
- Procedure-volume sensitivity (elective surgeries) tied to macro weakness or payer-driven utilization controls
- Pricing and reimbursement pressure from payors, including Medicare/MA dynamics and potential US policy shifts
- Competitive pressure from established device peers and emergent digital/therapeutic competitors
- Supply-chain and manufacturing execution risks that can disrupt product availability or increase costs
- Currency exposure and geopolitical risks affecting international revenue and margins
Latest MarketMoodz coverage
- BTIG Upgrades Medtronic to Buy; Stock Trades at Valuation Discount2026-06-04
- Tempus AI Stock Rises on ALERT Trial Boost for AI EHR2026-04-01
- GlucoTrack stock rises as data backs FDA filing plans for implantable CGM2026-03-27
- Medtronic, Genuine Parts And 3 Stocks To Watch Heading Into Tuesday2026-02-17
- Medtronic Wins FDA Nod for Spine System Aimed at Cutting Repeat Imaging2026-02-13
See today's live rating, score and targets
Members see the live hourly rating for MDT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.